<DOC>
	<DOCNO>NCT00616187</DOCNO>
	<brief_summary>A phase II open-label baseline-to-treatment trial design evaluate safety , tolerability efficacy orally administer atorvastatin patient relapsing-remitting multiple sclerosis ( RRMS ) . Patients least one gadolinium-enhancing lesion ( CEL ) screen magnetic resonance imaging ( MRI ) eligible study . Patients screen enrolled outpatient clinic Cecilie Vogt Clinic Charit√© - University Medicine Berlin . After baseline period 3 monthly MRI scan ( month -2 0 ) , patient follow 9-month treatment period 80 mg atorvastatin daily . The primary endpoint number CEL treatment month 6 9 compare baseline . Secondary endpoint include MRI-based parameter change clinical score immune response .</brief_summary>
	<brief_title>Atorvastatin Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>18 55 year old MS diagnosis accord McDonald criterion Relapsingremitting MS EDSS 0 6 Disease activity occurrence CEL brain MRI IFNbeta therapy least 6 month Primary chronic progressive MS Symptoms sign clinical disease condition similar MS Conditions disturb MRI measurement Clinically relevant GI disease eg Colitis ulcerosa , Crohns disease , history Ulcus pepticum Clinically relevant lung , heart , CNS , infectious disease Clinically relevant liver , kidney bone marrow abnormality ( define specific clinical chemistry value ) Allergies towards GdDTPA Allergies towards constituent therapeutic agent Recruitment clinical trial within 6 month prior study Pretreatment complete lymph irradiation , antibody therapy lymphocyte population ( eg . antiCD4 , Campath1H ) , mitoxantrone , cyclophosphamide , cyclosporin A , human antibody , immunomodulatory immunosuppressive agent include recombinant cytokine potential experimental MS therapy ( 6 month prior study start ) , glatiramer acetate , azathioprine , IVIg ( 6 month prior study start ) pregnancy lactation Alcohol drug abuse Inhibitors Cytochrom P 450 3A ( eg . cyclosporin , macrolide antibiotic , azole antimycotic ) . Medical psychological condition could hamper patient capacity understand patient information , give informed consent , adhere protocol study able complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>